ABOUT MAYZENT > EFFECTIVENESS & CLINICAL TRIAL

STAY AHEAD OF PROGRESSION
WITH MAYZENT

STAY AHEAD OF PROGRESSION
WITH MAYZENT

PROVEN RESULTS IN DELAYING DISABILITY PROGRESSION

In a 3-year clinical study, MAYZENT® was proven to significantly delay

Close Button

disability progression

Lingering or worsening of symptoms between relapses and over time, that leads to increased cognitive and physical disability.

in
people with

Close Button

relapsing multiple sclerosis (RMS)

A general term used for all forms of MS that have distinct episodes of relapses, including CIS, RRMS, and active SPMS.

. Disability progression was measured by assessing
3-month

Close Button

confirmed disability progression (CDP)

Any change in disability that remains consistent over a certain period of time.

with the

Close Button

Expanded Disability Status Scale (EDSS)

The EDSS is a method of measuring disability progression and monitoring changes in the level of disability over time. It is widely used in clinical studies and in the assessment of people living with multiple sclerosis (MS).

.


Take a look at the results below.

MAYZENT is the first and only pill proven to delay disability
progression, specifically studied in people with more progressed RMS.

OVERALL CLINICAL STUDY RESULTS FOR 3-MONTH CONFIRMED DISABILITY PROGRESSION

Nearly 3 out of 4 people taking MAYZENT showed no confirmed disability progression*

showed no confirmed
disability progression*

*Nearly 3 out of 4 is 74%,
compared to 68% taking

Close Button

placebo

A baseline inactive treatment given to one group in clinical trials to help researchers understand the efficacy of a new medical treatment.

.

21% lower chance of overall disability progression*

lower chance of overall
disability progression

Compared to those taking placebo.

The effect of MAYZENT was significant in people who had a relapse in the 2 years before the

, but not considered significant in people who had not.

Take a deeper look at MAYZENT efficacy with an MS expert in this video.

ADDITIONAL RESULTS FROM THE MAYZENT CLINICAL STUDY

No significant
difference between
MAYZENT and
placebo
in a timed
25-foot walk test

The timed 25-foot walk test measures how quickly someone can walk 25 feet.
The score is the average of two of these tests.

The timed 25-foot walk test measures how quickly someone can walk 25 feet.
The score is the average of two of these tests.

Because there was no significant difference in the walk test results, it can’t be determined by this study whether the following results were due to treatment with MAYZENT or if they happened by chance.

55% reduction in annual relapse rate (ARR)*

reduction in annual relapse
rate (ARR)
in people on MAYZENT vs placebo

ARR is the average number of


someone has in 1 year.

81% reduction in new or enlarging T2 lesions*

reduction in new or enlarging
t2 lesions.
The mean§ number of lesions was 0.70 for people on MAYZENT vs 3.60 for placebo

§The mean is the average number of new or enlarging

experienced over all visits.

23% reduction in brain volume loss (BVL)*

reduction in brain volume loss
(bvl)
in people on MAYZENT vs placebo

Brains typically lose volume as all people age. But in people with MS, tissue damage from inflammation and nerve damage can increase the rate at which people lose brain volume.

The change for those taking MAYZENT was 0.50% and 0.65% for those taking placebo.

“Every bit of improvement counts. I’ve noticed that MAYZENT
helps me to delay disability progression, and that gives me hope.”

BECKY E.,
A MAYZENT Mentor

Individual results may vary.

THE MAYZENT CLINICAL
STUDY WAS THE LARGEST
STUDY EVER OF PEOPLE
WITH PROGRESSING RMS

In this study, MAYZENT was found to be the first and only pill proven to delay disability progression in people with ore progressed RMS. All 1651 participants with progressing RMS had confirmed disability progression, with or without relapses, in the 2 years leading up to the study.

See below for some important characteristics. MAYZENT may help you stay ahead of disability progression, just like it did for people in the study.

Number of people in clinical trial: 1651. Average time since diagnosis: 13 years. Average age: 48. 78% had previously been on an MS treatment. 44% did not use a walking aid. 56% used a walking aid.

WHERE DO YOU FIT IN?

Fill out the fields below to see how you compare with people in the study.

How many years have you been diagnosed with MS?

0-5 years

6-10 years

10+ years

How old are you?

18-25

26-35

36-45

46-55

56-65

66+

Have you been on treatment before?

Yes

or

No

Do you currently, or have you ever, used a walking aid?

Yes

or

No

MRI=magnetic resonance imaging; MS=multiple sclerosis.

$0 CO-PAY OFFER

The Alongside MAYZENT support program will help navigate financial options, including $0 co-pay. See if you’re eligible.

STAY INFORMED, STAY AHEAD

Interested in starting MAYZENT? To help decide if it’s right for you, sign up to get information on RMS, tracking progression, MAYZENT effectiveness, and more.

IMPORTANT SAFETY INFORMATION AND INDICATION

COLLAPSE
EXPAND

IMPORTANT SAFETY INFORMATION

Do not take MAYZENT if you:

  • have a CYP2C9*3/*3 genotype. Before starting treatment with MAYZENT, your CYP2C9 genotype should be determined by your health care provider. Ask your health care provider if you are not sure.

  • have had a heart attack, chest pain called unstable angina, stroke or mini-stroke (transient ischemic attack or TIA), or certain types of heart failure in the last 6 months

What is MAYZENT® (siponimod) tablets?

MAYZENT is a prescription medicine that is used to treat relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

It is not known if MAYZENT is safe and effective in children.

  • have certain types of heart block or irregular or abnormal heartbeat (arrhythmia), unless you have a pacemaker

MAYZENT may cause serious side effects, including:

  1. Slow heart rate (bradycardia or bradyarrhythmia) when you start taking MAYZENT. MAYZENT can cause your heart rate to slow down, especially after you take your first dose. You should have a test to check the electrical activity of your heart called an electrocardiogram (ECG) before you take your first dose of MAYZENT.

    During the initial updosing period (4 days for the 1-mg daily dose or 5 days for the 2-mg daily dose), if you miss 1 or more doses of MAYZENT, you need to restart the updosing. Call your health care provider if you miss a dose of MAYZENT.

  2. Infections. MAYZENT can increase your risk of serious infections that can be life-threatening and cause death. MAYZENT lowers the number of white blood cells (lymphocytes) in your blood. This will usually go back to normal within 3 to 4 weeks of stopping treatment. Your health care provider should review a recent blood test of your white blood cells before you start taking MAYZENT.

    Call your health care provider right away if you have any of these symptoms of an infection during treatment with MAYZENT and for 3 to 4 weeks after your last dose of MAYZENT:

    • fever

    • tiredness

    • body aches

    • chills

    • nausea

    • vomiting

    • headache with fever, neck stiffness, sensitivity to light, nausea, confusion (these may be symptoms of meningitis, an infection of the lining around your brain and spine)

  3. A problem with your vision called macular edema. Macular edema can cause some of the same vision symptoms as a multiple sclerosis (MS) attack (optic neuritis). You may not notice any symptoms with macular edema. If macular edema happens, it usually starts in the first 1 to 4 months after you start taking MAYZENT. Your health care provider should test your vision before you start taking MAYZENT and any time you notice vision changes during treatment with MAYZENT. Your risk of macular edema is higher if you have diabetes or have had an inflammation of your eye called uveitis.

    Call your health care provider right away if you have any of the following: blurriness or shadows in the center of your vision, a blind spot in the center of your vision, sensitivity to light, or unusually colored (tinted) vision.

Before taking MAYZENT, tell your health care provider about all of your medical conditions, including if you:

  • have an irregular or abnormal heartbeat

  • have a history of stroke or other diseases related to blood vessels in the brain

  • have breathing problems, including during your sleep

  • have a fever or infection, or you are unable to fight infections due to a disease or are taking medicines that lower your immune system. Tell your health care provider if you have had chickenpox or have received the vaccine for chickenpox. Your health care provider may do a blood test for chickenpox virus. You may need to get the full course of vaccine for chickenpox and then wait 1 month before you start taking MAYZENT.

  • have slow heart rate

  • have liver problems

  • have diabetes

  • have eye problems, especially an inflammation of the eye called uveitis

  • had or now have a type of skin cancer called basal cell carcinoma (BCC), melanoma, or squamous cell carcinoma

  • have high blood pressure

  • are pregnant or plan to become pregnant. MAYZENT may harm your unborn baby. Talk to your health care provider right away if you become pregnant while taking MAYZENT or if you become pregnant within 10 days after you stop taking MAYZENT.

    • If you are a woman who can become pregnant, you should use effective birth control during your treatment with MAYZENT and for at least 10 days after you stop taking MAYZENT.

    • Pregnancy Registry: There is a registry for women who become pregnant during treatment with MAYZENT. If you become pregnant while taking MAYZENT, talk to your health care provider. For more information or to register, contact MotherToBaby by calling 1-877-311-8972, by sending an email to MotherToBaby@health.ucsd.edu, or go to www.mothertobaby.org/join-study.

  • are breastfeeding or plan to breastfeed. It is not known if MAYZENT passes into your breast milk. Talk to your health care provider about the best way to feed your baby if you take MAYZENT.

Tell your health care provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements. Especially tell your health care provider if you take medicines to control your heart rhythm (anti-arrhythmics), or blood pressure (antihypertensives), or heart beat (such as calcium channel blockers or beta-blockers); take medicines that affect your immune system, such as beta-interferon or glatiramer acetate, or any of these medicines that you took in the past.

Tell your health care provider if you have recently received a live vaccine. You should avoid receiving live vaccines during treatment with MAYZENT. MAYZENT should be stopped 1 week before and for 4 weeks after receiving a live vaccine. If you receive a live vaccine, you may get the infection the vaccine was meant to prevent. Vaccines may not work as well when given during treatment with MAYZENT.

MAYZENT may cause possible side effects, including:

  • increased blood pressure. Your health care provider should check your blood pressure during treatment with MAYZENT.

  • liver problems. MAYZENT may cause liver problems. Your health care provider should do blood tests to check your liver before you start taking MAYZENT. Call your health care provider right away if you have any of the following symptoms of liver problems:

    • nausea

    • vomiting

    • stomach pain

    • tiredness

    • loss of appetite

    • your skin or the whites of your eyes turn yellow

    • dark urine

  • breathing problems. Some people who take MAYZENT have shortness of breath. Call your health care provider right away if you have new or worsening breathing problems.

  • swelling and narrowing of the blood vessels in your brain. A condition called PRES (Posterior Reversible Encephalopathy Syndrome) has happened with drugs in the same class. Symptoms of PRES usually get better when you stop taking MAYZENT. However, if left untreated, it may lead to a stroke. Call your health care provider right away if you have any of the following symptoms: sudden severe headache, sudden confusion, sudden loss of vision or other changes in vision, or seizure.

  • severe worsening of multiple sclerosis after stopping MAYZENT. When MAYZENT is stopped, symptoms of MS may return and become worse compared to before or during treatment. Always talk to your doctor before you stop taking MAYZENT for any reason. Tell your health care provider if you have worsening symptoms of MS after stopping MAYZENT.

  • a type of skin cancer called basal cell carcinoma (BCC), melanoma, and squamous cell carcinoma. Tell your doctor if you have any changes in the appearance of your skin, including changes in a mole, a new darkened area on your skin, a sore that does not heal, or growths on your skin, such as a bump that may be shiny, pearly white, skin-colored, or pink. Your doctor should check your skin for any changes at the start of and during treatment with MAYZENT. Limit the amount of time you spend in sunlight and ultraviolet (UV) light. Wear protective clothing and use a sunscreen with a high sun protection factor.

The most common side effects of MAYZENT include: headache, high blood pressure (hypertension), and abnormal liver tests.

These are not all of the possible side effects of MAYZENT. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

What is MAYZENT® (siponimod) tablets?

MAYZENT is a prescription medicine that is used to treat relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

It is not known if MAYZENT is safe and effective in children.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information, including Medication Guide.